Aptevo Therapeutics Inc.
APVO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.01 | 0.04 |
| FCF Yield | -1,998.49% | -529.70% | -177.91% | -60.69% |
| EV / EBITDA | 0.08 | 0.27 | -0.28 | -1.80 |
| Quality | ||||
| ROIC | -262.17% | -163.91% | -104.12% | -63.86% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.99 | 0.67 | -2.62 | 0.76 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -10.26% | – |
| Free Cash Flow Growth | -102.77% | 44.28% | 5.99% | 23.85% |
| Safety | ||||
| Net Debt / EBITDA | 0.17 | 0.41 | 0.47 | 1.40 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3,165.75 | 0.00 | 293.03 | 108.80 |